Your browser doesn't support javascript.
loading
Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
Hermans, Lucas E; Moorhouse, Michelle; Carmona, Sergio; Grobbee, Diederick E; Hofstra, L Marije; Richman, Douglas D; Tempelman, Hugo A; Venter, Willem D F; Wensing, Annemarie M J.
Affiliation
  • Hermans LE; Translational Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands; Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa; Ndlovu Research Consortium, Elandsdoorn, South Africa.
  • Moorhouse M; Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.
  • Carmona S; Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa; National Health Laboratory Service, Johannesburg, South Africa.
  • Grobbee DE; Clinical Epidemiology, University Medical Center Utrecht, Utrecht, Netherlands; Ndlovu Research Consortium, Elandsdoorn, South Africa; Julius Center for Health Sciences and Primary Care, Utrecht, Netherlands.
  • Hofstra LM; Translational Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands.
  • Richman DD; Center for AIDS Research, University of California San Diego and VA San Diego Healthcare System, La Jolla, CA, USA.
  • Tempelman HA; Ndlovu Research Consortium, Elandsdoorn, South Africa; Ndlovu Care Group, Elandsdoorn, South Africa.
  • Venter WDF; Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa; Ndlovu Research Consortium, Elandsdoorn, South Africa.
  • Wensing AMJ; Translational Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands; Ndlovu Research Consortium, Elandsdoorn, South Africa. Electronic address: a.m.j.wensing@umcutrecht.nl.
Lancet Infect Dis ; 18(2): 188-197, 2018 02.
Article in En | MEDLINE | ID: mdl-29158101
ABSTRACT

BACKGROUND:

Antiretroviral therapy (ART) that enables suppression of HIV replication has been successfully rolled out at large scale to HIV-positive patients in low-income and middle-income countries. WHO guidelines for these regions define failure of ART with a lenient threshold of viraemia (HIV RNA viral load ≥1000 copies per mL). We investigated the occurrence of detectable viraemia during ART below this threshold and its effect on treatment outcomes in a large South African cohort.

METHODS:

In this observational cohort study, we included HIV-positive adults registered between Jan 1, 2007, and May 1, 2016, at 57 clinical sites in South Africa, who were receiving WHO-recommended ART regimens and viral load monitoring. Low-level viraemia was defined as the occurrence of at least one viral load measurement of 51-999 copies per mL during ART. Outcomes were WHO-defined virological failure (one or more viral load measurement of ≥1000 copies per mL) and switch to second-line ART. Risks were estimated with Cox proportional hazard models.

FINDINGS:

70 930 patients were included in the analysis, of whom 67 644 received first-line ART, 1476 received second-line ART, and 1810 received both. Median duration of follow-up was 124 weeks (IQR 56-221) for patients on first-line ART and 101 weeks (IQR 51-178) for patients on second-line ART. Low-level viraemia occurred in 16 013 (23%) of 69 454 patients, with an incidence of 11·5 per 100 person-years of follow-up (95% CI 11·4-11·7), during first-line ART. Virological failure during follow-up occurred in 14 380 (22%) of 69 454 patients on first-line ART. Low-level viraemia was associated with increased hazards of virological failure (hazard ratio [HR] 2·6, 95% CI 2·5-2·8; p<0·0001) and switch to second-line ART (HR 5·2, 4·4-6·1; p<0·0001]) compared with virological suppression of less than 50 copies per mL. Risk of virological failure increased further with higher ranges and persistence of low-level viraemia.

INTERPRETATION:

In this large cohort, low-level viraemia occurred frequently and increased the risk of virological failure and switch to second-line ART. Strategies for management of low-level viraemia need to be incorporated into WHO guidelines to meet UNAIDS-defined targets aimed at halting the global HIV epidemic.

FUNDING:

None.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / HIV-1 / Viral Load / Antiretroviral Therapy, Highly Active / Anti-Retroviral Agents Type of study: Clinical_trials / Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Africa Language: En Journal: Lancet Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2018 Type: Article Affiliation country: South Africa

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / HIV-1 / Viral Load / Antiretroviral Therapy, Highly Active / Anti-Retroviral Agents Type of study: Clinical_trials / Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Africa Language: En Journal: Lancet Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2018 Type: Article Affiliation country: South Africa